EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches

BACKGROUND: T-cell Acute Lymphoblastic Leukemia (ALL) represents about 10–15 % of pediatric ALL cases. EZH2, one of the components of Polycomb group proteins (PRC2) complex, catalyzes the trimethylation of histone H3 lysine 27 that is associated with transcriptional repression and tumor development....

Descripción completa

Detalles Bibliográficos
Autores principales: D’Angelo, V., Iannotta, A., Ramaglia, M., Lombardi, A., Zarone, M. R., Desiderio, V., Affinita, M. C., Pecoraro, G., Di Martino, M., Indolfi, P., Casale, F., Caraglia, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535295/
https://www.ncbi.nlm.nih.gov/pubmed/26268310
http://dx.doi.org/10.1186/s13046-015-0191-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535295/
https://www.ncbi.nlm.nih.gov/pubmed/26268310
http://dx.doi.org/10.1186/s13046-015-0191-0

Ejemplares similares